This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2003 Nov;285(5):R1250-2.

doi: 10.1152/ajpregu.00227.2003.

C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?

Gavin J Blake¹, Paul M Ridker

Affiliations

PMID: 14557240
DOI: 10.1152/ajpregu.00227.2003

Free article

Review

C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?

Gavin J Blake et al. Am J Physiol Regul Integr Comp Physiol. 2003 Nov.

Free article

. 2003 Nov;285(5):R1250-2.

doi: 10.1152/ajpregu.00227.2003.

Authors

Gavin J Blake¹, Paul M Ridker

Affiliation

¹ Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Ave. East, Boston, MA 02215, USA.

PMID: 14557240
DOI: 10.1152/ajpregu.00227.2003

No abstract available

PubMed Disclaimer

Comment in

C-reactive protein and atherothrombosis--beyond a biomarker: an actual partaker of lesion formation.
Verma S, Yeh ET. Verma S, et al. Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R1253-6; discussion R1257-8. doi: 10.1152/ajpregu.00170.2003. Am J Physiol Regul Integr Comp Physiol. 2003. PMID: 14557241 Review. No abstract available.

Similar articles

C-reactive protein and atherothrombosis--beyond a biomarker: an actual partaker of lesion formation.
Verma S, Yeh ET. Verma S, et al. Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R1253-6; discussion R1257-8. doi: 10.1152/ajpregu.00170.2003. Am J Physiol Regul Integr Comp Physiol. 2003. PMID: 14557241 Review. No abstract available.
C-reactive protein: a surrogate marker for atherosclerosis.
Davidson J, Rotondo D. Davidson J, et al. Curr Opin Lipidol. 2004 Jun;15(3):365-7. doi: 10.1097/00041433-200406000-00019. Curr Opin Lipidol. 2004. PMID: 15166795 No abstract available.
Update on C-reactive protein as a risk marker in cardiovascular disease.
Koenig W. Koenig W. Kidney Int Suppl. 2003 May;(84):S58-61. doi: 10.1046/j.1523-1755.63.s84.22.x. Kidney Int Suppl. 2003. PMID: 12694310 Review.
C-reactive protein: risk marker or mediator in atherothrombosis?
Jialal I, Devaraj S, Venugopal SK. Jialal I, et al. Hypertension. 2004 Jul;44(1):6-11. doi: 10.1161/01.HYP.0000130484.20501.df. Epub 2004 May 17. Hypertension. 2004. PMID: 15148294 Review.
The year in atherothrombosis.
Sanz J, Moreno PR, Fuster V. Sanz J, et al. J Am Coll Cardiol. 2010 Apr 6;55(14):1487-98. doi: 10.1016/j.jacc.2009.12.027. J Am Coll Cardiol. 2010. PMID: 20359599 Review. No abstract available.

See all similar articles

Cited by

Periodontal disease and risk of atherosclerotic coronary heart disease.
Nakajima T, Yamazaki K. Nakajima T, et al. Odontology. 2009 Jul;97(2):84-91. doi: 10.1007/s10266-009-0104-9. Epub 2009 Jul 29. Odontology. 2009. PMID: 19639450 Review.
Inflammation in atherosclerosis and diabetes mellitus.
Plutzky J. Plutzky J. Rev Endocr Metab Disord. 2004 Aug;5(3):255-9. doi: 10.1023/B:REMD.0000032414.17672.5c. Rev Endocr Metab Disord. 2004. PMID: 15211097 Review. No abstract available.
Periodontal, metabolic, and cardiovascular disease: Exploring the role of inflammation and mental health.
Makkar H, Reynolds MA, Wadhawan A, Dagdag A, Merchant AT, Postolache TT. Makkar H, et al. Pteridines. 2018 Feb;29(1):124-163. doi: 10.1515/pteridines-2018-0013. Epub 2018 Nov 13. Pteridines. 2018. PMID: 30705520 Free PMC article.
Correlations between plasma levels of a fibronectin isoform subpopulation and C-reactive protein in patients with systemic inflammatory disease.
Peters JH, Greasby T, Lane N, Woolf A. Peters JH, et al. Biomarkers. 2009 Jun;14(4):250-7. doi: 10.1080/13547500902836032. Biomarkers. 2009. PMID: 19489687 Free PMC article.
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.
Bocchia M, Galimberti S, Aprile L, Sicuranza A, Gozzini A, Santilli F, Abruzzese E, Baratè C, Scappini B, Fontanelli G, Trawinska MM, Defina M, Gozzetti A, Bosi A, Petrini M, Puccetti L. Bocchia M, et al. Oncotarget. 2016 Nov 1;7(44):72311-72321. doi: 10.18632/oncotarget.11100. Oncotarget. 2016. PMID: 27527867 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program